China Liquid Biopsy Market is expanding alongside developments in oncology, genomics, and personalized healthcare. The technology has attracted attention because it can obtain molecular information from body fluids without requiring the same type of invasive tissue collection associated with conventional biopsy procedures.

The increasing burden of cancer is one factor supporting interest in alternative diagnostic technologies. Healthcare professionals require effective tools for detecting cancer-related biomarkers, evaluating treatment response, and monitoring potential disease recurrence. Liquid biopsy technologies are being researched for these applications and are becoming an increasingly relevant part of the diagnostic technology landscape.

China's growing investment in healthcare and advanced genomic technologies is also creating favorable conditions for innovation. Next-generation sequencing has an important role in comprehensive genetic analysis, while digital PCR can provide highly sensitive detection of selected molecular targets.

The Market Research Future report estimates the China liquid biopsy market at USD 636.93 million in 2024 and forecasts growth to approximately USD 1.915 billion by 2035. The projected CAGR for 2025–2035 is around 10.53%.

Blood remains a major sample type because it can be collected relatively conveniently and can provide information about circulating biomarkers. At the same time, urine and other sample types are being investigated as researchers work to broaden liquid biopsy applications.

Future market development is likely to be influenced by research investments, diagnostic innovation, regulatory developments, and the growing use of precision medicine across China's healthcare system.

Dive into related studies for a broader industry perspective:

Kidney Dialysis Equipment Market Forecast

Aseptic Sampling Market Outlook

Overactive Bladder Treatment Market Analysis

Angiography Equipment Market Distribution

Guillain-Barre Syndrome Market Size